NCT05041153 2026-01-12
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
Clinical Trials
3 trialsNCT05733715 2025-03-03
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT06327269 2024-04-18
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase EARLY_PHASE1 Recruiting